Single Anastomosis Sleeve Jejunal (SAS-J) Bypass

Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A Treatment for Morbid Obesity

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02870530

Enrollment

200

Registered

2016-08-17

Start date

2016-11-30

Completion date

2017-04-30

Last updated

2022-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Brief summary

The purpose of this study is to determine the efficacy of single anastomoses sleeve jejunal bypass as a treatment for morbid obesity

Detailed description

in this study the investigators aim to test a new technique ( single anastomoses sleeve jejunal as a treatment for morbid obesity Which is a modification of Single anastomoses sleeve ileal bypass with short biliary limb ( about one third of the small intestine from the Duodeno-jejunal junction

Interventions

PROCEDURESingle Anastomosis Sleeve Jejunal (SAS-J) Bypass

Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* obese patients with BMI more than 40 * patients fit for laparoscopic surgery * give approval to share in the study

Exclusion criteria

* patients refused to share in the study * patients unfit for surgery * patients aged less than 18 and older than 50 * patients with BMI less than 50 * patient with previous upper abdominal surgery either for obesity or other diseases * patients with preoperative GERD clinically or by investigation

Design outcomes

Primary

Measure	Time frame	Description
operative time	the 1st 24 hours	the operative time from skin incision to skin closure
intraoperative complications	the 1st 24 hours	intraoperative complications like bleeding, other organs injuries
the postoperative weight loss	12 month	the percentage of weight loss from total excess body weight

Secondary

Measure	Time frame	Description
effect on metabolic syndrome if present	12 months	effect on blood sugar level, blood pressure and blood cholesterol level

Other

Measure	Time frame	Description
postoperative biliary reflux	3 months	the presence of postoperative biliary reflux clinically and by upper endoscopy

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026